Oncolytics Biotech (ONCY) Income from Continuing Operations (2009 - 2025)
Oncolytics Biotech's (ONCY) quarterly Income from Continuing Operations came in at 10829768.08 in Q3 2025, down 55.2% year-on-year from 24173684.79 in Q3 2024, and down 127.29% on a QoQ basis from 4764745.92 in Q2 2025.
Oncolytics Biotech (ONCY) Income from Continuing Operations (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has 17 years of Income from Continuing Operations data on file, last reported at 10829768.08 in Q3 2025.
- On a quarterly basis, Income from Continuing Operations fell 55.2% year-over-year to 10829768.08 in Q3 2025; TTM through Sep 2025 was 28278482.92, a 271.91% decrease from a year earlier, with the FY2025 full-year figure at 28759000.0, down 25.2% from the prior year.
- Income from Continuing Operations for Q3 2025 stood at 10829768.08, down from 4764745.92 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ONCY reached as high as 7333242.45 in Q3 2023 and fell as low as 35635822.99 in Q4 2021.
- Historically, Income from Continuing Operations has averaged 6167049.0 across 5 years, with a median of 5115936.85 in 2021.
- On a YoY basis, Income from Continuing Operations climbed as much as 331.24% in 2023 and fell as far as 242.15% in 2023.
- Year by year, Income from Continuing Operations stood at 35635822.99 in 2021, then increased by 15.98% to 29939607.48 in 2022, then soared by 90.67% to 2792704.07 in 2023, then slumped by 104.32% to 5706033.5 in 2024, then tumbled by 89.8% to 10829768.08 in 2025.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 10829768.08 in Q3 2025, 4764745.92 in Q2 2025, and 5706033.5 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10.83 Mn |
| Jun 30, 2025 | -4.76 Mn |
| Dec 31, 2024 | -5.71 Mn |
| Sep 30, 2024 | -6.98 Mn |
| Jun 30, 2024 | -5.17 Mn |
| Dec 31, 2023 | -2.79 Mn |
| Sep 30, 2023 | 7.33 Mn |
| Jun 30, 2023 | -5.58 Mn |
| Mar 31, 2023 | -4.76 Mn |
| Dec 31, 2022 | -29.94 Mn |
| Sep 30, 2022 | -3.17 Mn |
| Jun 30, 2022 | 3.93 Mn |
| Mar 31, 2022 | -5.39 Mn |
| Dec 31, 2021 | -35.64 Mn |
| Sep 30, 2021 | 3.80 Mn |
| Jun 30, 2021 | 5.93 Mn |
| Mar 31, 2021 | -5.12 Mn |
| Dec 31, 2020 | 27.36 Mn |
| Sep 30, 2020 | -5.12 Mn |
| Jun 30, 2020 | -5.03 Mn |